Butein-instigated MiR-186-5p-dependent Modulation of TWIST1 Affects Resistance to Cisplatin and Bioenergetics of Malignant Pleural Mesothelioma Cells

Overview

Journal Cancer Drug Resist

Date 2022 Sep 30

PMID 36176750

Authors

Mario Cioce

Daniela Rutigliano

Annamaria Puglielli

Vito Michele Fazio

Affiliations

Soon will be listed here.

Abstract

Malignant pleural mesothelioma is a chemoresistant tumor, and biphasic and sarcomatoid histologies portend the worst prognosis for malignant pleural mesothelioma (MPM) patients. We obtained the microRNA expression profile of three biphasic-sarcomatoid MPM cell lines to identify commonly expressed microRNAs and evaluate the effect of butein, a chemo-sensitizing compound, on this microRNA subset. Nanostring-based microRNA profiling and analysis through the ROSALIND platform were employed to identify the commonly modulated microRNAs and their targets. MicroRNA-mimic transfection, Luciferase assay, and Western blotting were employed to show specific perturbation of TWIST1 levels by miR-186-5p. Sphere-forming assays, invasion assay, and metabolic profiling were used to assess the biological consequences of the butein-instigated miR-186-5p-mediated perturbation of TWIST1 levels. TGCA analysis was used to search for the correlation between TWIST1 and miR-186-5p levels in biphasic and epithelioid MPM specimens. We identified a set of perturbed microRNAs, common to three biphasic/sarcomatoid MPM cell lines, after butein treatment. When focusing on miR-186-5p, we unraveled a butein-ignited and miR-186-5p-mediated modulation of TWIST1 levels which affected the 3D anchorage-independent growth, cisplatin resistance, invasion, and bioenergetics of the MPM cell lines tested. We showed that miR-186-5p and TWIST1 levels are anti-correlated in biphasic MPM specimens from TCGA. We unraveled a novel mechanism of action of butein, which attenuated the pro-tumorigenic features of MPM at least through a miR-186-5p-TWIST1 axis. We suggest that those activities converge into the chemo-sensitizing effect of this compound and may be of translational relevance.

Citing Articles

miRNA-503 inhibition exerts anticancer effects and reduces tumor growth in mesothelioma.

Piccioni M, Di Meo F, Valentino A, Campani V, Arigoni M, Tanori M J Exp Clin Cancer Res. 2025; 44(1):65.

PMID: 39984959 PMC: 11846362. DOI: 10.1186/s13046-025-03283-0.

Supragingival Bacterium Oral Infection-Induced Periodontitis and Robust miRNA Expression Kinetics.

Aravindraja C, Jeepipalli S, Duncan W, Vekariya K, Rahaman S, Chan E Int J Mol Sci. 2024; 25(11).

PMID: 38892405 PMC: 11172800. DOI: 10.3390/ijms25116217.

Predict lncRNA-drug associations based on graph neural network.

Xu P, Li C, Yuan J, Bao Z, Liu W Front Genet. 2024; 15:1388015.

PMID: 38737125 PMC: 11082279. DOI: 10.3389/fgene.2024.1388015.

Shake It Up Baby Now: The Changing Focus on TWIST1 and Epithelial to Mesenchymal Transition in Cancer and Other Diseases.

Mirjat D, Kashif M, Roberts C Int J Mol Sci. 2023; 24(24).

PMID: 38139368 PMC: 10743446. DOI: 10.3390/ijms242417539.

Unique miRomics Expression Profiles in -Infected Mandibles during Periodontitis Using Machine Learning.

Aravindraja C, Jeepipalli S, Duncan W, Vekariya K, Bahadekar S, Chan E Int J Mol Sci. 2023; 24(22).

PMID: 38003583 PMC: 10671577. DOI: 10.3390/ijms242216393.

References

Zhang Z, Zhang W, Mao J, Xu Z, Fan M . miR-186-5p Functions as a Tumor Suppressor in Human Osteosarcoma by Targeting FOXK1. Cell Physiol Biochem. 2019; 52(3):553-564. DOI: 10.33594/000000039. View

Cioce M, Canino C, Pass H, Blandino G, Strano S, Fazio V . Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma. J Exp Clin Cancer Res. 2021; 40(1):344. PMC: 8561918. DOI: 10.1186/s13046-021-02118-y. View

Meirson T, Pentimalli F, Cerza F, Baglio G, Gray S, Correale P . Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma. JAMA Netw Open. 2022; 5(3):e221490. PMC: 8908075. DOI: 10.1001/jamanetworkopen.2022.1490. View

Cioce M, Canino C, Pulito C, Muti P, Strano S, Blandino G . Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells. Cell Cycle. 2011; 11(1):132-40. DOI: 10.4161/cc.11.1.18474. View

Cioce M, Sacconi A, Pass H, Canino C, Strano S, Blandino G . Insights into Intra-Tumoral Heterogeneity: Transcriptional Profiling of Chemoresistant MPM Cell Subpopulations Reveals Involvement of NFkB and DNA Repair Pathways and Contributes a Prognostic Signature. Int J Mol Sci. 2021; 22(21). PMC: 8585077. DOI: 10.3390/ijms222112071. View

Asciak R, George V, Rahman N . Update on biology and management of mesothelioma. Eur Respir Rev. 2021; 30(159). PMC: 9489032. DOI: 10.1183/16000617.0226-2020. View

Del Peso G, Jimenez-Heffernan J, Bajo M, Aroeira L, Aguilera A, Fernandez-Perpen A . Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int Suppl. 2008; (108):S26-33. DOI: 10.1038/sj.ki.5002598. View

Doldi V, El Bezawy R, Zaffaroni N . MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. Cancers (Basel). 2021; 13(10). PMC: 8156532. DOI: 10.3390/cancers13102380. View

Manfredi M, Martinotti S, Gosetti F, Ranzato E, Marengo E . The secretome signature of malignant mesothelioma cell lines. J Proteomics. 2016; 145:3-10. DOI: 10.1016/j.jprot.2016.02.021. View

10.

Semina E, Rysenkova K, Troyanovskiy K, Shmakova A, Rubina K . MicroRNAs in Cancer: From Gene Expression Regulation to the Metastatic Niche Reprogramming. Biochemistry (Mosc). 2021; 86(7):785-799. DOI: 10.1134/S0006297921070014. View

11.

Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272):375-386. DOI: 10.1016/S0140-6736(20)32714-8. View

12.

Su C, Tang C, Chi M, Lin C, Fong Y, Liu Y . Resistin facilitates VEGF-C-associated lymphangiogenesis by inhibiting miR-186 in human chondrosarcoma cells. Biochem Pharmacol. 2018; 154:234-242. DOI: 10.1016/j.bcp.2018.05.001. View

13.

Zhang L, Chen W, Li X . A novel anticancer effect of butein: inhibition of invasion through the ERK1/2 and NF-kappa B signaling pathways in bladder cancer cells. FEBS Lett. 2008; 582(13):1821-8. DOI: 10.1016/j.febslet.2008.04.046. View

14.

Roberts C, Tran M, Pitruzzello M, Wen W, Loeza J, Dellinger T . TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling. Sci Rep. 2016; 6:37652. PMC: 5120297. DOI: 10.1038/srep37652. View

15.

Cao C, Sun D, Zhang L, Song L . miR-186 affects the proliferation, invasion and migration of human gastric cancer by inhibition of Twist1. Oncotarget. 2016; 7(48):79956-79963. PMC: 5346763. DOI: 10.18632/oncotarget.13182. View

16.

Kumar D, Lee B, Puan K, Lee W, Luis B, Yusof N . Resistin expression in human monocytes is controlled by two linked promoter SNPs mediating NFKB p50/p50 binding and C-methylation. Sci Rep. 2019; 9(1):15245. PMC: 6811637. DOI: 10.1038/s41598-019-51592-0. View

17.

Merikallio H, Paakko P, Salmenkivi K, Kinnula V, Harju T, Soini Y . Expression of snail, twist, and Zeb1 in malignant mesothelioma. APMIS. 2012; 121(1):1-10. DOI: 10.1111/j.1600-0463.2012.02931.x. View

18.

Wang X, Yin G, Zhang Z, Rong Z, Wang Z, Du D . TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer. Exp Cell Res. 2019; 386(1):111713. DOI: 10.1016/j.yexcr.2019.111713. View

19.

Jayasooriya R, Molagoda I, Park C, Jeong J, Choi Y, Moon D . Molecular chemotherapeutic potential of butein: A concise review. Food Chem Toxicol. 2017; 112:1-10. DOI: 10.1016/j.fct.2017.12.028. View

20.

Meijer H, Kong Y, Lu W, Wilczynska A, Spriggs R, Robinson S . Translational repression and eIF4A2 activity are critical for microRNA-mediated gene regulation. Science. 2013; 340(6128):82-5. DOI: 10.1126/science.1231197. View